The combination of efforts from several disciplines (including structural biology, immunology and neurobiology) and the assessment of mouse and human models, together with the generation of new selective pharmacological tools for TREM2/PLCγ2, will help to address these questions, and specifically modulate this pathway for protection/therapy against AD (Fig. 4). Here, PLCG2 is linked to Alzheimer disease.